mobocertinib,amivantamab-vmjw
takeda,janssen,genmab
['sclc', 'nsclc', 'rybrevant', 'exkivity', 'takeda', 'biotec']
#asco22: with median durability data, cullinan aims to 'distinguish itself' from takeda's exkivity and j&amp;j's rybrevant in exon 20 nsclc #strategy #competitiveintelligence #marketing #healthcare #pharma #productmarketing #pharmaceutical #biotech 
Strategy & Competitive Marketing | Digital & Social Pharma | Life Sciences Investment | Cell & Gene Therapy | Vaccines